Idelalisib is a first-in-class selective, oral, phosphatidylinositol 3-kinase delta (PI3Kδ)
inhibitor approved for the treatment of several types of blood cancer. Idelalisib has …

Background The prognosis of patients with early relapsed or refractory large B-cell
lymphoma after the receipt of first-line chemoimmunotherapy is poor. Methods In this …

Background New treatments have improved outcomes for patients with relapsed chronic
lymphocytic leukemia (CLL), but complete remissions remain uncommon. Venetoclax has a …

Background Patients with relapsed chronic lymphocytic leukemia (CLL) who have clinically
significant coexisting medical conditions are less able to undergo standard chemotherapy …

Background Patients with relapsed or refractory mantle-cell lymphoma who have disease
progression during or after the receipt of Bruton's tyrosine kinase (BTK) inhibitor therapy …

Abstract Treatment decisions for patients with chronic lymphocytic leukemia (CLL) are
dependent on symptoms and classification into high-, medium-, or low-risk categories. The …

Background Acalabrutinib is a selective, covalent Bruton tyrosine-kinase inhibitor with
activity in chronic lymphocytic leukaemia. We compare the efficacy of acalabrutinib with or …

Background Irreversible inhibition of Bruton's tyrosine kinase (BTK) by ibrutinib represents
an important therapeutic advance for the treatment of chronic lymphocytic leukemia (CLL) …

Purpose B-cell leukemia/lymphoma-2 (BCL-2) overexpression is common in many non-
Hodgkin lymphoma (NHL) subtypes. A phase I trial in patients with NHL was conducted to …

Adoptive immunotherapy with T cells expressing a tumor-specific chimeric T-cell receptor is
a promising approach to cancer therapy that has not previously been explored for the …